secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001140361-24-037428
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups
--------------------------------------------------------------------------------

- PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
- Tecovirimat showed clinical benefit vs. placebo in patients treated ≤7 days from symptom onset and those with ≥100 lesions.
- Safety profile comparable to placebo; consistent with prior studies over 15 years.
- Four additional randomized trials (STOMP, UNITY, Platinum-CAN, EPOXI) are ongoing.
- Trial hospitalized all patients, which may have reduced measured benefit vs. real-world settings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124037428/0001140361-24-037428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124037428/ef20034039_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-037428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer